BridgeBio Oncology Therapeutics, Inc. (BBOT)
NASDAQ: BBOT · Real-Time Price · USD
12.31
+0.13 (1.07%)
Nov 28, 2025, 4:00 PM EST - Market closed

BBOT Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023
Period Ending
Sep '25 Dec '24 Dec '23
Net Income
-114.93-74.28-64.7
Depreciation & Amortization
0.470.210.09
Loss (Gain) From Sale of Investments
-1.56-1.54-
Stock-Based Compensation
3.514.4316.47
Other Operating Activities
8.490.56-
Change in Accounts Payable
2.532.50.27
Change in Other Net Operating Assets
14.7913.1-4.2
Operating Cash Flow
-86.7-55.03-52.08
Capital Expenditures
-0.54-0.05-0.41
Investment in Securities
91.66-122.89-
Other Investing Activities
-2.41-2.41
Investing Cash Flow
91.12-120.53-2.82
Issuance of Common Stock
373.511.113.62
Financing Cash Flow
384.04206.2955.12
Net Cash Flow
388.4630.730.23
Free Cash Flow
-87.24-55.08-52.49
Free Cash Flow Per Share
-7.82-379.51-420.87
Levered Free Cash Flow
--42.53-
Unlevered Free Cash Flow
--42.53-
Change in Working Capital
17.3215.59-3.94
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.